文献速递MDS 与骨髓增殖性肿瘤

CALR突变细胞对蛋白酶体与内质网应激反应联合抑制敏感

CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response.
PubMed 文献 · Leukemia · 2022-12-06

该研究在CALR突变骨髓增殖性肿瘤(MPN)中发现,CALR突变造血干细胞与巨核祖细胞中未折叠蛋白、蛋白酶体及内质网应激反应上调;联合抑制蛋白酶体和IRE1-XBP1轴在体内优先靶向Calr突变细胞并改善MPN表型,但六周联合抑制后连续移植未发现Calr突变长期造血干细胞优先耗竭。

要点

  • CALR突变造血干细胞和巨核祖细胞中未折叠蛋白、蛋白酶体和内质网应激反应差异上调。
  • 联合抑制蛋白酶体与IRE1-XBP1轴在体内优先靶向Calr突变细胞并改善MPN表型。
  • 六周联合抑制后连续移植未发现Calr突变长期造血干细胞优先耗竭。

核心结论

  • 利用Calr突变MPN中改变的蛋白质稳态可识别可能用于治疗获益的组合依赖性,并提示根除疾病传播性Calr突变长期造血干细胞可能需要更持续的治疗。

研究设计与样本

  • 研究在CALR突变MPN中鉴定未折叠蛋白、蛋白酶体和内质网应激反应的差异上调,并在体内评估蛋白酶体与IRE1-XBP1轴联合药理抑制对Calr突变造血干细胞和巨核系细胞的作用,以及六周联合抑制后的连续移植实验。

主要发现

  • CALR突变造血干细胞和巨核祖细胞中未折叠蛋白、蛋白酶体和内质网应激反应差异上调。
  • 联合药理抑制蛋白酶体和内质网应激反应的IRE1-XBP1轴在体内优先靶向Calr突变造血干细胞和巨核系细胞而非野生型细胞,并改善MPN表型。
  • 联合蛋白酶体/IRE1抑制六周后的连续移植实验中,未发现Calr突变长期造血干细胞优先耗竭。

临床怎么用

  • 原文结论提示利用Calr突变MPN中改变的蛋白质稳态识别组合依赖性可能用于治疗获益,并提示根除疾病传播性Calr突变长期造血干细胞可能需要更持续的治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cancer is driven by somatic mutations that provide a fitness advantage. While targeted therapies often focus on the mutated gene or its direct downstream effectors, imbalances brought on by cell-state alterations may also confer unique vulnerabilities. In myeloproliferative neoplasms (MPN), somatic mutations in the calreticulin (CALR) gene are disease-initiating through aberrant binding of mutant CALR to the thrombopoietin receptor MPL and ligand-independent activation of JAK-STAT signaling. Despite these mechanistic insights into the pathogenesis of CALR-mutant MPN, there are currently no mutant CALR-selective therapies available. Here, we identified differential upregulation of unfolded proteins, the proteasome and the ER stress response in CALR-mutant hematopoietic stem cells (HSCs) and megakaryocyte progenitors. We further found that combined pharmacological inhibition of the proteasome and IRE1-XBP1 axis of the ER stress response preferentially targets Calr-mutated HSCs and megakaryocytic-lineage cells over wild-type cells in vivo, resulting in an amelioration of the MPN phenotype. In serial transplantation assays following combined proteasome/IRE1 inhibition for six weeks, we did not find preferential depletion of Calr-mutant long-term HSCs. Together, these findings leverage altered proteostasis in Calr-mutant MPN to identify combinatorial dependencies that may be targeted for therapeutic benefit and suggest that eradicating disease-propagating Calr-mutant LT-HSCs may require more sustained treatment.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Jutzi JS, Marneth AE, Jiménez-Santos MJ, et al. CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response. Leukemia. 2022. PMID: 36473980. doi:10.1038/s41375-022-01781-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。